Reported 1 day ago
Recursion Pharmaceuticals has secured complete rights to REV102, a potential oral therapy for hypophosphatasia, a rare bone disorder. The acquisition from Rallybio Corporation is valued at up to $25 million, with an initial payment of $7.5 million. REV102 is currently in preclinical development as an ENPP1 inhibitor and is linked to a collaboration focused on innovative treatments for HPP.
Source: YAHOO